Dolutegravir (DTG), a second-generation integrase strand transfer inhibitor, is recommended as first-line treatment for people living with HIV (PLWH) in low- and middle-income countries (1). However, co-administering DTG with rifampicin (RIF), a potent inducer, may reduce DTG concentrations, potentially leading to treatment failure (2). This study aimed to determine the population pharmacokinetics of DTG and […]
